Achhammer I, Metz P
Clinical Development and Project Development, Boehringer Mannheim GmbH, Federal Republic of Germany.
Drugs. 1991;41 Suppl 3:80-91. doi: 10.2165/00003495-199100413-00009.
Diuretics belong to the class of antihypertensive drugs recommended for first-line therapy of essential hypertension. Although they are widely and effectively used for the treatment of hypertension, the question remains whether their possible negative influence on metabolic and electrolyte parameters could partly offset the benefit of blood pressure reduction with respect to reduction of coronary artery disease. Recently published data demonstrate that much lower doses of thiazides exert the same antihypertensive effect as the higher doses used in the past and even prescribed today. These lower doses produce relatively little change in biochemical parameters. Thus, the postulated risks can be avoided by using the lowest effective dose. Traditionally, loop diuretics of the furosemide (frusemide) type are rarely used as first-line antihypertensive agents. They seem to display less efficacy coupled with an intense diuresis when used in standard available doses. However, there is evidence that newly developed loop diuretics, in lower doses than used in congestive heart failure, are effective antihypertensive agents. For example, torasemide 2.5mg once daily, which does not exert a significant diuresis over 24 hours compared with placebo, lowers elevated blood pressure to a similar extent than thiazides or related compounds. This antihypertensive effect is accompanied by less, if any, changes in metabolic or electrolyte parameters compared with widely used standard diuretics such as hydrochlorothiazide, indapamide or chlorthalidone. The influence on serum potassium and magnesium is similar to or even less than fixed combinations of hydrochlorothiazide and triamterene or amiloride. Thus, low-dose torasemide constitutes an alternative to established thiazide antihypertensive therapy.
利尿剂属于推荐用于原发性高血压一线治疗的抗高血压药物类别。尽管它们被广泛且有效地用于治疗高血压,但问题仍然存在,即它们对代谢和电解质参数可能产生的负面影响是否会部分抵消降低血压对减少冠状动脉疾病的益处。最近发表的数据表明,与过去甚至现在仍在使用的高剂量相比,噻嗪类药物的剂量大幅降低却能发挥相同的抗高血压作用。这些较低剂量在生化参数方面产生的变化相对较小。因此,通过使用最低有效剂量可以避免假定的风险。传统上,呋塞米(速尿)类型的袢利尿剂很少用作一线抗高血压药物。当以标准可用剂量使用时,它们似乎疗效较低且伴有强烈的利尿作用。然而,有证据表明,新开发的袢利尿剂以低于用于充血性心力衰竭的剂量使用时,是有效的抗高血压药物。例如,托拉塞米每日一次2.5毫克,与安慰剂相比,在24小时内不会产生显著的利尿作用,其降低血压升高的程度与噻嗪类药物或相关化合物相似。与广泛使用的标准利尿剂如氢氯噻嗪、吲达帕胺或氯噻酮相比,这种抗高血压作用伴随的代谢或电解质参数变化较少(如果有变化的话)。对血清钾和镁的影响与氢氯噻嗪和氨苯蝶啶或阿米洛利的固定组合相似甚至更小。因此,低剂量托拉塞米构成了既定噻嗪类抗高血压治疗的替代方案。